Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Trial Profile

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Influenza virus vaccine (NasoVAX) (Primary)
  • Indications Influenza A virus infections
  • Focus Adverse reactions; Proof of concept
  • Sponsors Altimmune
  • Most Recent Events

    • 21 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 20 Sep 2017 According to an Altimmune media release, the company have been cleared by the FDA to initiate this trial.
    • 21 Aug 2017 According to an Altimmune media release, Company has submitted an Investigational New Drug (IND) application to the U.S Food and Drug Administration (FDA) for this phase II trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top